Messenger RNA (mRNA) therapies are shaping the future of medicine from personalized vaccines to treatments for rare diseases. Yet, producing these therapies at scale remains a significant challenge due to the complexity of manufacturing processes, regulatory hurdles, and the need for precise, high-quality operations. Download our white paper Digital Excellence in Nuclear Acid Therapy to explore how digital tools can support your mRNA production goals.

To overcome these challenges, life sciences companies are increasingly turning to digital technologies. A well-defined digital strategy supported by advanced tools like digital twins, process automation, real-time analytics, and contextualized data management is key to enabling scalable, efficient, and compliant mRNA therapy production.

Digital twins can help simulate and optimize complex bioprocesses, reducing risk during scale-up. Process automation minimizes human error, improves reproducibility, and accelerates manufacturing timelines. Real-time monitoring ensures the fragile mRNA molecules are handled under optimal conditions, while advanced analytics allow for predictive insights that improve decision-making across R&D, clinical, and commercial manufacturing stages.

Emerson, in collaboration with AspenTech, offers a comprehensive suite of solutions that support mRNA therapy production from discovery through to commercialization. These include the DeltaV™ DCS for process control, AspenTech Inmation™ for contextual data management, and advanced performance tools to ensure regulatory compliance and manufacturing excellence.

Together, these tools form the backbone of a robust digital strategy that can help pharmaceutical manufacturers bring therapies to market faster, at scale, and with consistent quality.

Download our white paper Digital Excellence in Nuclear Acid Therapy to explore how digital tools can support your mRNA production goals.